A high-throughput, multi-index isothermal amplification platform for rapid detection of 19 types of common respiratory viruses including SARS-CoV-2
Fast and accurate diagnosis and the immediate isolation of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are regarded as the most effective measures to restrain the coronavirus disease 2019 (COVID-19) pandemic. Here, we present a high-throughput, multi-index nuc...
- Autores:
- Tipo de recurso:
- Review article
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13403
- Acceso en línea:
- https://www.sciencedirect.com/science/article/pii/S2095809920302381?via%3Dihub
http://hdl.handle.net/20.500.12010/13403
https://doi.org/10.1016/j.eng.2020.07.015
- Palabra clave:
- COVID-19
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
Coronavirus disease 2019
Severe acute respiratory syndrome coronavirus 2
Microfluidics
Nucleic acid testing
Isothermal amplification
- Rights
- License
- Abierto (Texto Completo)
Summary: | Fast and accurate diagnosis and the immediate isolation of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are regarded as the most effective measures to restrain the coronavirus disease 2019 (COVID-19) pandemic. Here, we present a high-throughput, multi-index nucleic acid isothermal amplification analyzer (RTisochipTM-W) employing a centrifugal microfluidic chip to detect 19 common respiratory viruses, including SARS-CoV-2, from 16 samples in a single run within 90 min. The limits of detection of all the viruses analyzed by the RTisochipTM-W system were equal to or less than 50 copies per microliter, which is comparable to those of conventional reverse-transcription polymerase chain reaction. We also demonstrate that the RTisochipTM-W system possesses the advantages of good repeatability, strong robustness, and high specificity. Finally, we analyzed 201 cases of preclinical samples, 14 cases of COVID-19-positive samples, 25 cases of clinically diagnosed samples, and 614 cases of clinical samples from patients or suspected patients with respiratory tract infections using the RTisochipTM-W system. The test results matched the referenced results well and reflected the epidemic characteristics of the respiratory infectious diseases. The coincidence rate of the RTisochipTM-W with the referenced kits was 98.15% for the detection of SARS-CoV-2. Based on these extensive trials, we believe that the RTisochipTM-W system provides a powerful platform for fighting the COVID-19 pandemic. |
---|